Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Preventing Infections After Esophageal Cancer Surgery Using Colistin Sulfate, Tobramycin, and Amphotericin B in Patients with Resectable Esophageal Cancer

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment on patients with esophageal cancer, a type of cancer that occurs in the esophagus, the tube that carries food from the throat to the stomach. The treatment being tested is called "Basis voor SDD suspensie," which is an oral suspension containing two active substances: colistin sulfate and tobramycin. Additionally, the study involves the use of amphotericin B, a medication that is mixed with the SDD suspension. These medications are being tested to see if they can help prevent severe infections, particularly pneumonia, after surgery to remove part of the esophagus, known as an esophagectomy.

The purpose of this study is to evaluate how effective the treatment is in reducing the risk of infections after esophagectomy. Participants in the study will receive the treatment for a period of up to seven days. The study will monitor the occurrence of infections, such as pneumonia, within 30 days after surgery. The trial will also look at other possible complications, including infections in different parts of the body, leakage at the surgical site, and overall recovery after surgery.

Throughout the study, researchers will collect information on the health and recovery of participants, including their quality of life and any additional surgeries or hospital stays needed. The study aims to provide valuable insights into improving the care and outcomes for patients undergoing surgery for esophageal cancer.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient is required to provide written informed consent. This confirms understanding and agreement to participate in the trial.

  2. Step 2

    Pre-surgery medication

    The patient will begin taking an oral suspension called Basis voor SDD suspensie, which contains the active substances colistin sulfate and tobramycin. This medication is administered to help prevent infections.

    Additionally, the patient will take amphotericin B as an oral suspension. The specific dosage and frequency will be provided by the healthcare team.

  3. Step 3

    Surgery

    The patient will undergo a transthoracic esophagectomy, a surgical procedure intended to remove esophageal cancer. This is performed with curative intent.

  4. Step 4

    Post-surgery monitoring

    After surgery, the patient will be monitored for any signs of postoperative pneumonia and other infectious complications. This includes checking for symptoms such as fever, changes in white blood cell count, and purulent secretions.

    The healthcare team will also monitor for anastomotic leakage, which may require further intervention if detected.

  5. Step 5

    Follow-up assessments

    The patient will have follow-up assessments to evaluate the incidence of any postoperative complications within 30 days after surgery.

    Quality of life will be assessed at 30 days, 3 months, and 6 months after surgery using specific questionnaires.

  6. Step 6

    Long-term monitoring

    The patient will be monitored for all-cause mortality within 90 days after surgery.

    The length of stay in the intensive care unit and the total hospital stay will be recorded, including any readmissions within 6 months after surgery.

  7. Step 7

    Cost evaluation

    Direct and indirect costs related to the patient's hospital stay and societal costs up to 6 months after surgery will be estimated using specific questionnaires.

Who can join the trial?

6 criteria

  • The patient must have a diagnosis of primary **esophageal adenocarcinoma** or **squamous cell carcinoma**. These are types of cancer found in the esophagus.
  • The cancer should be located in the mid or distal esophagus or at the level of the **gastro-esophageal junction**, which is where the esophagus meets the stomach.
  • The patient should be scheduled for a **transthoracic esophagectomy**, which is a surgery to remove part or all of the esophagus, with the aim of curing the cancer.
  • The patient may also be scheduled for **esophageal reconstruction** using a part of the stomach or small intestine.
  • The patient must be 18 years of age or older.
  • The patient must be able to give written informed consent, meaning they understand the study and agree to participate.

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with esophageal cancer cannot participate. Esophageal cancer is a type of cancer that occurs in the esophagus, the tube that carries food from the mouth to the stomach.
  • Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups who may have a higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

SDD (Selective Decontamination of the Digestive tract) is a treatment used in this trial to prevent severe infections, particularly pneumonia, after esophagectomy surgery. This therapy involves using specific antibiotics to reduce harmful bacteria in the digestive tract, aiming to lower the risk of infections that can occur after the surgical removal of part of the esophagus.

What is already known about the treatment

Selective Decontamination of the Digestive Tract (SDD) – This treatment is administered orally and topically within the digestive tract. It is currently being studied in clinical trials for its potential to reduce severe infections, particularly pneumonia, following esophagectomy in patients with esophageal cancer. The main therapeutic indication is to prevent postoperative infections by reducing harmful bacteria in the digestive system. SDD works by using a combination of non-absorbable antibiotics that target specific bacteria, thereby minimizing the risk of infection. It is classified under antimicrobial prophylaxis.

Investigated diseases

Esophageal Cancer – Esophageal cancer is a disease where malignant cells form in the tissues of the esophagus, the tube that carries food from the throat to the stomach. It often begins in the cells lining the inside of the esophagus and can grow to invade deeper layers and nearby structures. As the cancer progresses, it may cause symptoms such as difficulty swallowing, weight loss, and chest pain. The disease can spread to lymph nodes and other parts of the body, including the liver and lungs. The progression of esophageal cancer can vary, with some types growing more quickly than others.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-504144-33-01Protocol code114329Estimated enrolment853 patientsSponsorStichting Radboud universitair medisch centrum

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).